The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution
Open accessAbstract
The ubiquitin-proteasome system (UPS) has been implicated in neurodegenerative diseases based on the presence of deposits consisting of ubiquitylated proteins in affected neurons. It has been postulated that aggregation-prone proteins associated with these disorders, such as α-synuclein, β-amyloid peptide, and polyglutamine proteins, compromise UPS function, and delay the degradation of other proteasome substrates. Many of these substrates play important regulatory roles in signaling, cell cycle progression, or apoptosis, and their inadvertent stabilization due to an overloaded and improperly functioning UPS may thus be responsible for cellular demise in neurodegeneration. Over the past decade, numerous studies have addressed the UPS dysfunction hypothesis using various model systems and techniques that differ in their readout and sensitivity. While an inhibitory effect of some disease proteins on the UPS has been demonstrated, increasing evidence attests that the UPS remains operative in many disease models, which opens new possibilities for treatment. In this review, we will discuss the paradigm shift that repositioned the UPS from being a prime suspect in the pathophysiology of neurodegeneration to an attractive therapeutic target that can be harnessed to accelerate the clearance of disease-linked proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
Bett, J. S., Cook, C. N., Petrucelli, L., & Bates, G. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005128 · Cited by 62
Ubiquitin crosstalk connecting cellular processes
Groothuis, T. A., Dantuma, N. P., Neefjes, J., & Salomons, F. A. (2006) · Cell Division · doi:10.1186/1747-1028-1-21 · Cited by 60
Self-citationMimicking proteasomal release of polyglutamine peptides initiates aggregation and toxicity
Raspe, M. A., Gillis, J., Krol, H. A., Schipper-Krom, S., Bosch, K. S., van Veen, H. A., & Reits, E. A. (2009) · Journal of Cell Science · doi:10.1242/jcs.045567 · Cited by 58
Mayer, R. J., Lowe, J. S., Lennox, G. G., Doherty, F., & Landon, M. (1989) · PubMed · Cited by 57
Aquilano, K., Rotilio, G., & Ciriolo, M. R. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01783.x · Cited by 52
Monitoring the ubiquitin/proteasome system in conformational diseases
Lindsten, K., & Dantuma, N. P. (2003) · Ageing Research Reviews · doi:10.1016/s1568-1637(03)00031-x · Cited by 51
Self-citationMandrusiak, L. M. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg161 · Cited by 49
Modulating huntingtin half‐life alters polyglutamine‐dependent aggregate formation and cell toxicity
Kaytor, M. D., Wilkinson, K. D., & Warren, S. T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02376.x · Cited by 48
Proteasome Function Is Inhibited by Polyglutamine-expanded Ataxin-1, the SCA1 Gene Product
Park, Y., Hong, S., Kim, S.-J., & Kang, S. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)13132-3 · Cited by 48
Proteasomes Cleave at Multiple Sites within Polyglutamine Tracts
Pratt, G. W., & Rechsteiner, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709347200 · Cited by 46
Ubiquitin — omics reveals novel networks and associations with human disease
Kessler, B. M. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.024 · Cited by 46
Furrer, S. A., Waldherr, S. M., Mohanachandran, M. S., Baughn, T. D., Nguyen, K.-T., Sopher, B. L., Damian, V. A., Garden, G. A., & Spada, A. R. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds495 · Cited by 45
Kalmár, B., Edet-Amana, E., & Greensmith, L. (2012) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2012.660953 · Cited by 43
Ishigaki, S., Niwa, J., Yamada, S.-I., Takahashi, M., Ito, T., Sone, J., Doyu, M., Urano, F., & Sobue, G. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.017 · Cited by 43
Casciati, A., Ferri, A., Cozzolino, M., Celsi, F., Nencini, M., Rotilio, G., & Carrì, M. T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01232.x · Cited by 41
Liu, Y., Hettinger, C. L., Zhang, D., Rezvani, K. S., Wang, X., & Wang, H. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-0022-9 · Cited by 34
Palazzolo, I., Nedelsky, N. B., Askew, C. E., Harmison, G. G., Kasantsev, A. G., Taylor, J. P., Fischbeck, K. H., & Pennuto, M. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22389 · Cited by 28
Silencing Polyglutamine Degeneration with RNAi
Bonini, N. M., & Spada, A. R. L. (2005) · Neuron · doi:10.1016/j.neuron.2005.11.008 · Cited by 25
Kong, F., Zhang, J., Li, Y., Hao, X., Ren, X., Li, H., & Zhou, P. (2013) · Oncogene · doi:10.1038/onc.2013.33 · Cited by 13
Rezvani, N., Elkharaz, J., Lawler, K., Mee, M., Mayer, R. J., & Bedford, L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.070 · Cited by 9
Ectopic Targeting of Substrates to the Ubiquitin Pathway
Zhang, J., & Zhou, P. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99053-8 · Cited by 5
Cited by
The logic of the 26S proteasome.
Collins, G. A., & Goldberg, A. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.023 · Cited by 933
“Decreased 26S activity has often been suggested in models of neurodegenerative disease (Dantuma and Bott, 2014) and even cardiac disease (Ranek et al., 2013).”
Remaining mysteries of molecular biology: the role of polyamines in the cell
Miller-Fleming, L., Olin-Sandoval, V., Campbell, K., & Ralser, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.06.020 · Cited by 658
Protein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675
“Defects in both the UPS and autophagy pathways of protein degradation are often seen in neurodegenerative diseases [79, 80].”
BackgroundParkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
Elusive roles for reactive astrocytes in neurodegenerative diseases
Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453
Metadata
- Authors
- Dantuma, N. P., & Bott, L. C.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-07-31
- Volume
- 7
- Pages
- 70-70
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2114452685
- Cited by
- 338
- References
- 221
- FWCI
- 9.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.